Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four agents used in peripheral nerve blocks to provide extended analgesia. Bupivacaine is an amide local anesthetic that blocks nerve impulse generation and conduction by inhibiting voltage-gated sodium channels[8]. Epinephrine acts as a vasoconstrictor that prolongs the duration of local anesthetics and serves as a marker for intravascular injections[3]. Dexamethasone is a corticosteroid that significantly extends the duration of sensory and motor blockade when added to local anesthetics[1][4]. Clonidine is an alpha-2 adrenergic agonist that enhances and prolongs the analgesic effects of local anesthetics[3][6]. When combined, these agents work synergistically to provide superior analgesia with prolonged duration. Studies have shown that adding dexamethasone to a bupivacaine-epinephrine-clonidine interscalene block significantly prolongs sensory block (1457 vs. 833 minutes) and motor blockade (1374 vs. 827 minutes) compared to control groups, while also reducing opioid requirements in the first 24 hours post-procedure[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bupivacaine, epinephrine, dexamethasone, and clonidine combination.